Brief: Allena Pharmaceuticals Qtrly Net Loss Per Share $0.46

Allena Pharmaceuticals

07/03/2019 13:06

March 7 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR 2018
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    * QTRLY NET LOSS PER SHARE $0.46
    * Q4 EARNINGS PER SHARE VIEW $-0.51 -- REFINITIV IBES DATA
    * PHASE 3 URIROX-1 AND URIROX-2 TRIALS ONGOING; URIROX-1
TOPLINE
DATA EXPECTED IN SECOND HALF OF 2019
    * LOUIS BRENNER, M.D. APPOINTED CHIEF EXECUTIVE OFFICER
    * EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION
WITH FDA
IN SECOND HALF OF 2019 FOR ALLN-346
    * EXPECTS TO INITIATE FIRST CLINICAL TRIAL IN FIRST HALF OF
2020
FOR ALLN-346

Source text for Eikon:  ID:nGNX6wv4gq 
Further company coverage:  ALNA.O 

 (((Reuters.Briefs@thomsonreuters.com);;))